Multidrug-resistant tuberculosis

QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance

Retrieved on: 
Wednesday, April 24, 2024
TST, Genetically modified bacteria, WHO, Virtual reality, CDC, Multidrug-resistant tuberculosis, Bacteria, AMR, ESCMID, QIAGEN, ECCMID, MDR-TB, WGS, Doctor of Philosophy, Research, Workflow, Sputum, NGS, PCR, Disease, Patient, Panel, Mycobacterium tuberculosis, QGEN, Gold, Infection, D20, Emerging, Tuberculosis, Cerebrospinal fluid, Vaccine

The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).

Key Points: 
  • The QIAseq xHYB Mycobacterium tuberculosis Panel represents a major advancement in solving the problem of bacterial WGS from complex host samples, using next-generation sequencing (NGS).
  • By eliminating the need for a 4-to-6-week bacterial culture, the panel significantly accelerates the process of obtaining results.
  • “The introduction of the QIAseq xHYB Mycobacterium tuberculosis Panel reflects our ongoing commitment to address global health challenges like TB and antimicrobial resistance,” said Nitin Sood, Vice President, Head of the Life Sciences Business Area at QIAGEN.
  • The QIAseq xHYB Mycobacterium tuberculosis Panel also plays a vital role in the detection and management of antimicrobial resistance (AMR), a growing concern in TB treatment.

Yes! We Can End TB & AIDS, Says AHF

Retrieved on: 
Friday, March 22, 2024
White House, Federal Government, Public Policy, Other Health, General Health, Women, Philanthropy, Advocacy Group Opinion, Infectious Diseases, Government, Men, LGBTQ+, Foundation, Other Philanthropy, AIDS, Consumer, Health, Coinfection, AIDS Healthcare Foundation, Tuberculosis, World Tuberculosis Day, HIV, Global health, Education, Death, Infection, World Health Organization, Multidrug-resistant tuberculosis, TB, MDR-TB, AHF, Multimedia, Pharmaceutical industry

We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.

Key Points: 
  • We Can End TB & AIDS’ commemorations to honor the millions of lives lost to TB while urging leaders at all levels of government to prioritize TB prevention, testing, and treatment efforts.
  • View the full release here: https://www.businesswire.com/news/home/20240322482439/en/
    AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe.
  • Integrating TB prevention and care into HIV programs, which AHF has done, is essential for comprehensive healthcare.
  • We Can End TB & AIDS.’”
    According to the World Health Organization, TB claimed 1.3 million lives in 2022, including 167,000 people living with HIV, with an estimated nearly 11 million people falling ill to TB worldwide.

ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy

Retrieved on: 
Monday, January 22, 2024
Death, Stellenbosch University, Patient, Research, Cytokine, TB, Partnership, Science, Global health, Melinda French Gates, Bill, Risk, Infection, Blood, Disease, COVID-19, HIV/AIDS, Laboratory, Tuberculosis, Protein, HIV, Fluid mechanics, Physician, Biomarker, Machine learning, Multidrug-resistant tuberculosis, Nobel Prize, Pharmaceutical industry

ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring.

Key Points: 
  • ProteinLogic extends ImmiPrint® Technology to address TB antimicrobial chemotherapy response monitoring.
  • CAMBRIDGE, UK (2024-01-22) – ProteinLogic, a biomarker discovery and commercialization company and Stellenbosch University, today announced that they have received a $1.35 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ImmiPrint® Technology to monitor treatment responses to TB antimicrobial chemotherapy.
  • ProteinLogic has forged a partnership with Stellenbosch University, South Africa, renowned for their significant contributions to global TB research.
  • The ability to monitor clinical responses to TB antimicrobial chemotherapy and the potential to predict TB antimicrobial chemotherapy responses at an early timepoint, will have a significant impact on the duration of clinical trials for new TB antimicrobial chemotherapies.

AHF Slams Johnson & Johnson for Immoral Profiteering on TB Treatment

Retrieved on: 
Tuesday, September 19, 2023
Medical Supplies, AIDS, Other Health, Health, General Health, Public Policy, Pharmaceutical, Other Policy Issues, Infectious Diseases, Government, Advocacy Group Opinion, AHF, Bedaquiline, TB, Medicine, Death, Multidrug-resistant tuberculosis, Patent, Tuberculosis, AIDS Healthcare Foundation, MDR-TB, Johnson & Johnson, Pharmaceutical industry

The AIDS Healthcare Foundation (AHF) today strongly condemned pharma giant Johnson & Johnson (J&J) for again putting profits before people’s lives by charging South Africa more than twice what many other countries are paying for the multidrug-resistant tuberculosis (MDR-TB) medicine SIRTURO (bedaquiline) and extending its patent another four years.

Key Points: 
  • The AIDS Healthcare Foundation (AHF) today strongly condemned pharma giant Johnson & Johnson (J&J) for again putting profits before people’s lives by charging South Africa more than twice what many other countries are paying for the multidrug-resistant tuberculosis (MDR-TB) medicine SIRTURO (bedaquiline) and extending its patent another four years.
  • “While shocking, this move by Johnson & Johnson is unfortunately not surprising – we demand that the company halt its profiteering tactics immediately and sell South Africa bedaquiline at the same cost countries are paying through Stop TB Partnership’s Global Drug Facility .
  • Additionally, J&J must avail the patent for the lifesaving treatment so that generic drug manufacturers can produce the medicine at affordable prices,” said Dr. Kate Ssamula, Country Program Director for AHF South Africa.
  • “We have one of the highest rates of MDR-TB globally, and tuberculosis is the leading cause of death for South Africans, with 56,000 TB deaths in 2021 alone.

Global Point Of Care Diagnostics Market 2022: Developments Including AI Integration Drive Sector Forward - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health Technology, Health, Medical Supplies, Medical Devices, Cloud, Drug, Hospital, Texas Homecare, Respiratory syncytial virus, USD, Time-invariant system, Prevalence, Postprandial glucose test, Fasting, United Nations, HBV, End, HIV/AIDS, Diabetes, HSV, Conditional sentence, Coagulation testing, RSV, Population, Microfluidics, HPV, Diagnosis, Artificial intelligence, HCV, CDC, CAGR, Multidrug-resistant tuberculosis, Urinary tract infection, Infection, Time, Virus, IDF, Cancer, DOA, Rheumatism, Product, First Nations in Ontario, Patient, Analysis, Death, Respiratory tract infection, MRSA, TB, HIV, Degenerative disease, COVID-19, POC, Medical device, Pharmaceutical industry, Vaccine, Pneumonia

The "Global Point Of Care Diagnostics Market, By Product type, By End users, By Platform- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Point Of Care Diagnostics Market, By Product type, By End users, By Platform- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The increase in the prevalence of chronic and infectious diseases in developing economies is one of the point of care diagnostics market growth factor.
  • Global Point of Care Diagnostics Market is segmented based on product type, end users, and platform.
  • Based on end users, global point of care diagnostics market is further segmented into clinics, hospitals, homecare, assisted living healthcare facilities, laboratory.

BSV along with experts raise awareness on Superbugs post World Antimicrobial Awareness Week

Retrieved on: 
Friday, December 3, 2021
Patient, MDR, Sex, Bacteria, Drug of last resort, WHO, Virus, University of Port Harcourt Teaching Hospital, University, View, Risk, Malaria, Infection, Bacterial pneumonia, Medical specialty, Hospital, Multidrug-resistant tuberculosis, Fungus, Immune system, Multimedia, Immunization, Urinary tract infection, Vaccine

According to Dr. Awopeju AT of the University of Port Harcourt Teaching Hospital, "Superbugs are microorganisms that are resistant to many antibiotics.

Key Points: 
  • According to Dr. Awopeju AT of the University of Port Harcourt Teaching Hospital, "Superbugs are microorganisms that are resistant to many antibiotics.
  • These superbugs could be drug-resistant bacteria, viruses or fungi which are difficult to treat posing a threat.
  • Dr. Unigwe, Infectious Disease Specialist from UNTH thinks that a recent rise in superbugs is partly to do with the overuse of antibiotics.
  • Experts are also tracking data on antibiotic-resistant infections to develop specific strategies to prevent those infections.

BSV along with experts raise awareness on Superbugs post World Antimicrobial Awareness Week

Retrieved on: 
Friday, December 3, 2021
Patient, MDR, Sex, Bacteria, Drug of last resort, WHO, Virus, University of Port Harcourt Teaching Hospital, University, Risk, Malaria, Infection, Bacterial pneumonia, Medical specialty, Hospital, Multidrug-resistant tuberculosis, Fungus, Immune system, Immunization, Urinary tract infection, Vaccine

According to Dr. Awopeju AT of the University of Port Harcourt Teaching Hospital, "Superbugs are microorganisms that are resistant to many antibiotics.

Key Points: 
  • According to Dr. Awopeju AT of the University of Port Harcourt Teaching Hospital, "Superbugs are microorganisms that are resistant to many antibiotics.
  • These superbugs could be drug-resistant bacteria, viruses or fungi which are difficult to treat posing a threat.
  • Dr. Unigwe, Infectious Disease Specialist from UNTH thinks that a recent rise in superbugs is partly to do with the overuse of antibiotics.
  • Appropriate use of antibiotics, developing new antibiotics and new diagnostic tests are the other strategies to track development of resistance.

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline

Retrieved on: 
Monday, August 9, 2021
Pharmaceutical, Health, Clinical Trials, Health, Mouse, Creativity, OAPI, Union, Mycobacterium tuberculosis, Safety, Bill & Melinda Gates Foundation, Nephrology, CEO, Cardiology, Gates, Adult, LinkedIn, Overalls, Tuberculosis, Twitter, European Union, Ethambutol, Bill, MDR-TB, TB, Mortality, Maintenance, Medication, Patient, Melinda Gates, Multidrug-resistant tuberculosis, Isoniazid, Heart, Commercialization, Pyrazinamide, Mental health, Pharmaceutical industry, Silviculture, OPC-167832, delamanid (DELTYBA), Otsuka, OPC-167832, DELAMANID (DELTYBA), OTSUKA

Data gathered from this landmark trial will hopefully improve current management of TB and improve patient adherence by significantly shortening the duration of treatment.

Key Points: 
  • Data gathered from this landmark trial will hopefully improve current management of TB and improve patient adherence by significantly shortening the duration of treatment.
  • In 2017, Otsuka completed a phase 1, single-ascending-dose study of OPC-167832.
  • The phase 2 trial of OPC-167832, delamanid (DELTYBA) and bedaquiline (SIRTURO) is expected to begin in 2022 with results available in 2024.
  • Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.

Ending tuberculosis is a race against time and drug resistance

Retrieved on: 
Monday, March 22, 2021
Tuberculosis, Health, Articles, Clinical medicine, Tuberculosis management, Multidrug-resistant tuberculosis, Pandemic, TB Alert, World Tuberculosis Day

Regional TB mortality has gone down, declining by 9.4% between 2018 and 2019.

Key Points: 
  • Regional TB mortality has gone down, declining by 9.4% between 2018 and 2019.
  • This is notably higher than the average global decline in TB mortality (3.7%) and enough to have reached the End TB Strategy milestone of a 35% reduction by 2020 compared to 2015.
  • However, TB is second only to COVID-19 as an infectious disease that kills, and drug resistance is a major concern.
  • There are also worrying indications that the COVID-19 pandemic may stall progress or cause significant setbacks in the fight against TB.

The uneven burden of TB

    • In 2019, there were an estimated 20000 TB deaths in the WHO European Region equivalent to 2.2 deaths per 100000 people, and some 3560 TB deaths occurred in the European Union/European Economic Area (EU/EEA), equal to 0.7 deaths per 100000.
    • For 2019, in the European Region as a whole, there were some 216000 new TB diagnoses, corresponding to 23.2 cases per 100000.
    • Twenty-nine countries in the EU/EEA reported a total of 47504 TB cases, which equates to a rate of 9.2 cases per 100000.
    • Across the EU/EEA, most country-specific rates continue to decline; however, the EU/EEA as a whole is currently not on track to reach the goal of ending TB by 2030.
    • TB is far from being evenly distributed in the European Region.

COVID-19’s impact on TB

    • The decrease in TB burden put the Region on course to reach the End TB Strategy milestone for 2020 and the regional action plan target for reduction of the TB incidence rate.
    • Negative impacts have already been observed in TB service delivery and notifications in high-burden countries, this is believed to indicate that fewer people have been tested, meaning that people with undiagnosed TB are not getting the treatment they need and run the risk of infecting others.
    • The findings of an ongoing assessment of the impact of COVID-19 on TB services and spread in the European Region, will be ready in Spring 2021.

Treatment outcomes remain suboptimal

    • Despite universal access to quality-assured anti-TB drugs, treatment outcomes in the Region remain suboptimal.
    • Treatment success in the EU/EEA was lower still, with only 64% of all TB cases notified in 2018 being reported as having completed their treatment successfully.
    • Across the Region, treatment outcomes for MDR-TB remain suboptimal.
    • Unsuccessful treatment is one of the factors that drives resistance, often due to lack of effective TB medicines in treatment regimens for drug-resistant TB, and low adherence to therapy.
    • In the European Region, only 52% of coinfected patients complete TB treatment successfully, far below the global rate of 76%.

TB at centre of health agendas

    • Stella Kyriakides, European Commissioner for Health and Food Safety stated: The decline of tuberculosis in recent years is positive news.
    • But TB continues to be a threat to some regions in the EU and continues to affect the most vulnerable in our society.
    • Together with our agencies, the Commission is committed to playing its part to eliminate TB through, in part, funding, research and the fight against antimicrobial resistance.
    • However, despite this progress, the EU/EEA is not currently on track to reach the goal of ending the TB epidemic by 2030.

Read the annual surveillance report



    Publication

Tuberculosis surveillance and monitoring in Europe 2021 –2019 data

    Notes to editors